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Abstract
The problem of targeted delivery of antisense and siRNA oligonucleotides can be resolved into
two distinct aspects. The first concerns devising ligand-oligonucleotide or ligand-carrier moieties
that bind with high selectivity to receptors on the cell type of interest and that are efficiently
internalized by endocytosis. The second concerns releasing oligonucleotides from
pharmacologically inert endomembrane compartments so that they can access RNA in the cytosol
or nucleus. In this review we will address both of these aspects. Thus we present information on
three important receptor families, the integrins, the receptor tyrosine kinases, and the G protein-
coupled receptors in terms of their suitability for targeted delivery of oligonucleotides. This
includes discussion of receptor abundance, internalization and trafficking pathways, and the
availability of suitable high affinity ligands. We also consider the process of oligonucleotide
uptake and intracellular trafficking and discuss approaches to modulating these processes in a
pharmacologically productive manner. Hopefully the basic information presented in this review
will be of value to investigators involved in designing delivery approaches for oligonucleotides.
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Introduction
Currently there is immense interest in the potential therapeutic applications of both single
and double stranded oligonucleotides. Multiple clinical trials of siRNA, classical antisense
oligonucleotides and splice switching oligonucleotides are underway (Bennett and Swayze,
2010; Burnett and Rossi, 2012) and research at the level of cellular and animal studies is
increasingly active. However, oligonucleotide-based therapies face two formidable unsolved
problems.
The first entails controlling the selectivity of action so as to avoid unintended side effects.
Part of this issue involves off-target effects at the molecular level (Singh et al., 2011) while
another aspect concerns effects mediated through the innate immune system (Sioud, 2009).
However, yet another important aspect involves the delivery of the oligonucleotide to the
tissue of interest. While in some cases the oligonucleotide may target an RNA that is
uniquely expressed in a certain tissue or disease state, in many other instances the RNA
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there have been many attempts to deliver oligonucleotides in a selective manner, for
example, to tumor cells rather than normal cells or to sites of inflammation rather than
normal tissue, but thus far these attempts have been only partially successful (Juliano et al.,
2009; Nguyen and Szoka, 2012).
The second key unsolved problem involves the access of oligonucleotides to their sites of
action in the cytosol or nucleus. These relatively large and highly polar molecules do not
cross lipid bilayer membranes. Thus, under most circumstances, they are accumulated in
cells by endocytosis and much of the accumulated material remains entrapped in
endomembrane compartments and is thus pharmacologically inert (Juliano et al., 2012a).
There have been many attempts to address this problem using polymeric or lipid-based
delivery systems, but once again success has been limited.
The intent of this review is to inform investigators interested in oligonucleotide-based
therapeutics about the possibilities and limitations involved in targeted delivery. First, we
will discuss the internalization and intracellular trafficking of oligonucleotides. Second, we
will discuss several cell surface receptor families that may have the potential to support
selective delivery to particular cells or tissues, with emphasis on integrins, receptor tyrosine
kinases (RTKs) and G Protein-Coupled Receptors (GPCRs), as well as several specific
receptors in heart and liver. Finally we will analyze how receptor targeting and intracellular
trafficking can be manipulated to enhance the pharmacological effects of oligonucleotides.
This review reflects our opinion that oligonucleotide-based therapeutics will benefit greatly
from a biologically sophisticated approach to receptor targeting and intracellular trafficking.
It should be noted that the review does not provide a survey of recent publications on
oligonucleotide delivery; rather it focuses on the underlying biology of receptors,
endocytosis and trafficking.
Endocytosis and Trafficking Pathways
Antisense and siRNA oligonucleotides, either in unmodified form, as conjugates, or
associated with most nanocarriers, usually enter cells via endocytosis (Juliano et al., 2012a).
However, this broad statement fails to reveal the complexities inherent in the existence of
diverse pathways of internalization and intracellular trafficking that are based upon intricate
and highly selective protein machinery.
Endocytosis Mechanisms
It is clear that there exist multiple pathways of endocytosis in addition to the well-known
clathrin coated pit pathway (Doherty and McMahon, 2009; Howes et al., 2010). A simplified
depiction of some of these pathways is shown in Figure 1. During classical clathrin-
mediated endocytosis, cell surface receptors and their bound ligands associate with adapter
proteins such as AP-2, and with a host of accessory factors, that drive the receptors into
specialized membrane areas subtended by a meshwork of clathrin triskelions. The clathrin
network, along with specialized BAR domain proteins such as SNX9 and amphiphysin that
sense and promote membrane curvature, contribute to invagination of the clathrin bounded
membrane area. This is quickly followed by pinching off of a clathrin-coated vesicle
through the action of the dynamin GTPase (Doherty and McMahon, 2009). The coated
endosome then uncoats under the influence of auxilin and hsc70 and the uncoated vesicle is
then ready to begin its intracellular journey. Some of the receptors and ligands internalized
via the clathrin pathway include the LDL receptor, transferrin receptor, and many agonist
liganded GPCRs (Wolfe and Trejo, 2007)
The caveolar pathway is also of great interest (Lajoie and Nabi, 2010). Many cells display
small plasma membrane invaginations that are rich in cholesterol and sphingolipids and that
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contain caveolin1, a 21kD protein that inserts a hydrophobic loop into the membrane.
Additionally, the cavins are coat proteins that help stabilize caveolae. Although there is still
some controversy as to whether caveolae generate independent intracellular vesicles or
whether they remain as tubular structures linked to the plasma membrane, substantial
evidence suggests that caveolae generate vesicles that contribute to intracellular membrane
traffic. Generally caveolae are smaller (<100 nanometers) than other types of endocytotic
vesicles. The caveolar pathway is known to internalize Cholera toxin, SV40 virus, and GPI-
linked membrane proteins; however, some of these moieties are also internalized by other
pathways. Dynamin is likely involved in the disjunction of caveolae, but the evidence is not
as clear as for clathrin-coated vesicles. Many additional proteins have been observed to be
associated with caveolae; in particular these structures are rich in signal transduction
proteins (Sorkin and von Zastrow, 2009).
Several clathrin- and caveolin-independent pathways have also been delineated to various
extents. An interesting internalization mechanism is the CLIC/GEEC pathway that may be
particularly important for fluid phase endocytosis (Doherty and McMahon, 2009). The
acronym is for Clathrin and Dynamin Independent Carriers (CLIC)/GPI-AP Enriched Early
Endosomal Compartments (GEEC). This pathway gives rise to tubular endosomes that are
rich in GPI-linked proteins and that typically incorporate large volumes of extracellular
fluid. Thus they can be visualized using fluid phase markers such as dextrans. As the name
implies, dynamin is not necessary for the formation of these vesicles; rather membrane
disjunction may involve GRAF1, a GTPase activating protein that has a BAR domain
(Howes et al., 2010). Additional clathrin and caveolin independent pathways exist (Doherty
and McMahon, 2009) including a dynamin-dependent pathway for internalization of the
IL2-receptor and the FCεR1 immunoglobulin receptor, and a dynamin-independent pathway
linked to the internalization of MHC class I histocompatibility proteins. The flotillins are
membrane-inserted proteins involved in ordering lipid domains and supporting endocytosis.
Both Cholera toxin and GPI-linked proteins have been associated with flotillin-rich
membrane microdomains. There is evidence that dynamin is not needed for internalization
of cargo via flotillin containing vesicles (Glebov et al., 2006). Macropinocytosis is a process
quite different from other forms of endocytosis. It involves cell protrusions pinching off
large volumes of extracellular fluid and is thus an important contributor to fluid phase
endocytosis (Kerr and Teasdale, 2009). Generation of the relatively large macropinosomes
involves the actinomyosin contractile machinery and its typical regulators including the Rac
GTPase and PAK family kinases. The actin cytoskeleton plays a key role in most
internalization events; however, not all forms of endocytosis require actin. For example,
certain arenaviruses enter cells via a pathway that is independent of clathrin, caveolin,
dynamin and actin (Kunz, 2009). Surprisingly, we recently observed that phosphorothioate
antisense oligonucleotides also enter cells by a clathrin, caveolin, dynamin and actin
independent pathway (Alam et al., 2010).
Intracellular Trafficking
Whether in unmodified form, as a chemical conjugate, or associated with a nanocarrier, an
oligonucleotide accumulating in a cell by endocytosis enters a complex network of
trafficking pathways that can lead to many intracellular destinations. Some of the key
subcellular membrane bound compartments include early and recycling endosomes, late
endosomes/multi-vesicular bodies, lysosomes, the Golgi apparatus and the endoplasmic
reticulum. (see Figure 2). Trafficking is not random, but rather it is a carefully orchestrated
process that allows the cell to deliver endogenous and exogenous materials to the most
appropriate place. Several pathogens have learned to exploit these pathways; for example
certain viruses as well as some bacterial toxins traffic via the so-called retrograde transport
process (Pfeffer, 2011) and are thus delivered to the trans-Golgi compartment and thence to
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cytosol. In many ways this is similar to the goal of oligonucleotide delivery, that is to exit
from membrane bound compartments and access the cytosol and nucleus.
During the past few years there has been great progress in understanding the molecular
mechanisms of intracellular trafficking (Huotari and Helenius, 2011). In essence, all
membrane trafficking involves the same basic steps: (i) a small coated vesicle is pinched off
from a larger donor membrane bound compartment; (ii) the vesicle is uncoated permitting
the display of tethering and fusion proteins; (iii) the vesicle migrates to its destination along
cytoskeletal ‘tracks’ provided by actin- or tubulin- based filaments; (iv) the vesicle uses
tethering proteins to recognize the recipient membrane compartment and then utilizes
SNARE proteins to engage in fusion and deliver membrane and contents to the target
compartment (Angers and Merz, 2011). A simplified diagram of this process is shown in
Figure 2. There are numerous variations on this theme, but the overall picture is quite clear.
Important aspects of intracellular trafficking are regulated and controlled by the Rab family
of proteins. The Rabs are a large family of small GTPases (over 60 members) (Stenmark,
2009) and are the best known proteins that temporally and spatially regulate membrane
trafficking and signaling (Schwartz et al., 2007). They are molecular switches, cycling
between active GTP-bound and inactive GDP-bound forms. Similar to other small GTPases,
their activity is regulated by Rab-specific GEFs (Guanine nucleotide Exchange Factors),
GAPs (GTPase Activating Proteins) and GDIs (GDP Dissociation Inhibitors) (Grosshans et
al., 2006). Activated Rab GTPases act as molecular scaffolds to regulate membrane
trafficking including vesicle budding, cytoskeletal transport, and targeted docking and
fusion. Hence, they represent attractive targets for genetic manipulation aimed at unraveling
mechanism of membrane trafficking. For example, mutants of the Rab GTPases (Rab7
N125I, Rab5 Q79L, Rab5 S34N) cause dramatic changes in both endosome membrane
fusion and morphology (Feng et al., 1995; Stenmark et al., 1994). Thus dominant negative
or constitutively activated versions of Rab proteins can potentially be used as molecular
tools to probe the intracellular trafficking of oligonucleotides. Additionally, since different
Rabs are preferentially associated with different endomembrane compartments, they can
serve as marker proteins. This aspect has already been exploited in probing the trafficking of
oligonucleotides (Ming et al., 2010).
In our estimation, a fuller understanding of the intracellular trafficking patterns of various
types of oligonucleotides (and of the delivery agents used for these molecules) will greatly
enhance the possibility of rational and productive development of oligonucleotides as
therapeutic agents. Thus, we believe, an investment in basic research on trafficking will
ultimately pay off in terms of drug development.
Receptor Families for Oligonucleotide Delivery
Here we discuss aspects of several families of cell surface receptors that seem to have
substantial potential in terms of supporting selective delivery of antisense or siRNA. We
will describe their basic structural and functional characteristics, their expression levels and
distribution, their modes of internalization, trafficking and recycling, and the availability of
specific, high affinity ligands. Ideally, one would like to be able to utilize a receptor that is
expressed in only one tissue or disease state, that is abundant, that internalizes rapidly and
extensively, and for which selective high affinity ligands are readily available. Obviously,
all existing receptors fall short of this ideal. However, there are many instances where
individual receptors have at least some of these ideal characteristics.
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Members of the integrin family of heterodimeric cell surface receptors play multiple critical
roles in development and in the adult organism (Hynes, 2002a; Juliano, 2002; Schwartz,
2010). Because of their ubiquity and relatively abundant expression integrins have been a
favorite mediator for selective delivery of both oligonucleotides and small molecules
(Juliano et al., 2011). In mammals the integrin family is comprised of 18 alpha subunits and
8 beta subunits that form 24 individual heterodimers (Margadant et al., 2011). Each subunit
has a large extracellular domain, a single transmembrane segment, and a relatively short
cytoplasmic tail. The normal ligands for integrins are primarily various large extracellular
matrix (ECM) proteins such as fibronectin, laminins and collagens (Hynes, 2002a) (see
Figure 3), but the discovery that the short peptide sequence arg-gly-asp (RGD) could bind to
certain integrins (Pierschbacher and Ruoslahti, 1984) has led to the development of many
small molecule ligands, as further discussed below. The cytoplasmic tails of integrins
associate with proteins such as talin, filamin and kindlin that can then link to actin filaments.
Thus integrins provide a mechanochemical linkage between the ECM and the cytoskeleton;
during cell adhesion integrins and their multiple associated proteins cluster to form a variety
of organized but dynamic structures including focal contacts, fibrillar adhesions, podosomes
and others (Margadant et al., 2011; Schwartz, 2010).
Integrin Signaling—In addition to their structural role, integrins are highly involved in
signal transduction processes. Integrin signaling has often been divided into ‘inside out
signaling’ and ‘outside in signaling’. The former refers to the fact that integrins can exist in
activated, inactive or intermediate states, in response to external cues. The solution of the
crystal structure of the external domain of the αvβ3 integrin (Xiong et al., 2001), followed
by further progress on structure and function, has been very helpful in understanding
integrin activation. Thus, in the inactive state the integrin external domain is thought to be in
a bent configuration while the cytoplasmic tails are closely juxtaposed by charge-charge
interaction. In the active form the external domain is extended and the tails separate. The
association of the cytosolic protein talin with the beta subunit tail is the key final step in
integrin activation (Kim et al., 2011; Margadant et al., 2011). However, a multiplicity of
other proteins, particularly the small GTPase Rap1, are involved in the regulation of ‘inside
out signaling’. Perhaps the most dramatic example of this process concerns the unique
platelet integrin αIIbβ3 whose affinity for its physiological ligand fibrinogen is vastly
increased in response to signaling molecules released at wound sites, leading to platelet
aggregation and thrombus formation.
So-called ‘outside in signaling’ (from extracellular space to cytosol) involving integrins is a
very complex story that we can only briefly touch upon. Integrins can both signal directly
and also strongly influence signaling pathways primarily mediated through other receptors
(Streuli and Akhtar, 2009). Thus one aspect involves integrins forming complexes with
receptor tyrosine kinase (RTKs) that then affect the ability of the RTK to become activated
by its normal ligand (Cabodi et al., 2004). Integrin engagement with ECM can also modulate
the classic Erk/MAP Kinase pathway downstream from RTK activation (Juliano et al.,
2004). This involves regulation at the level of the Raf-1 kinase (Edin and Juliano, 2005; Lin
et al., 1997) and also effects on the trafficking of activated Erk to the nucleus (Aplin et al.,
2001). (see Figure 4).
Integrins can also signal directly via activation of tyrosine kinases. The discovery that cell
adhesion or integrin clustering could activate tyrosine phosphorylation via focal adhesion
kinase (FAK) was a key event in understanding the function of integrins (Kornberg et al.,
1991; Schaller et al., 1992). FAK autophosphorylation subsequent to integrin engagement
leads to the recruitment of several SH2 and SH3 domain proteins, particularly c-Src
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(Parsons, 2003). Recruitment of Src leads to additional tyrosine phosphorylations with
several consequences including recruitment of the SH2-adaptor Grb2 in complex with SOS,
a GEF for Ras, leading to activation of the Ras-MAP Kinase cascade. Further, SH3 domains
mediate binding of GRAF and ASAP1, which are GAPs for the Rho and Arf 1/6 small
GTPases, leading to effects on the actin cytoskeleton. Additionally the adaptor protein Cas
and its partner Crk recruit the DOCK180/ELMO complex which acts as a GEF for the Rac
GTPase and thus to further effects on the cytoskeleton. Finally, the adaptor protein paxilin
binds to a sequence in the c-terminal of FAK and serves both as a structural protein linking
to actin, and as an adaptor for the PKL-PIX-PAK complex thus bringing PAK kinase to the
focal adhesion where it can regulate LIM-kinase and myosin light chain kinase and also
influence the Erk pathway via Raf-1. Increasingly, the integrin-FAK connection is seen as a
key mediator of the activity of Rho-family GTPases and their cytokeletal functions
(Huveneers and Danen, 2009). Thus FAK serves as the hub of a multi-protein signal
transduction complex that influences cell cycle, cytoskeletal organization, and cell motility.
(See Figure 4 for a visualization of Integrin, RTK and GPCR signaling).
Yet another modality of integrin signaling involves the activation of the growth factor TGF-
β by certain integrins, particularly αvβ6, αvβ8, αvβ5 (Munger and Sheppard, 2011). TGF-β
is released from cells as a latent multi-protein complex that includes an inhibitory pro-
peptide termed LAP; integrin binding to LAP then releases functional TGF-β, which Mcan
Mthen Minitiate MitsM signalingM cascade. Interestingly one of the consequences of TGF-
β activity is up-regulation of certain integrins, thus creating a very complex feedback loop.
Integrin Trafficking and Recycling—It has been known for many years that integrins
are internalized and usually recycle to the cell surface (Bretscher, 1992; Sczekan and
Juliano, 1990). Recently, these processes and their implications have been explored in more
detail and the critical role of Rab GTPases identified (Caswell et al., 2009; Margadant et al.,
2011). At one time it was thought that integrin recycling allowed transport of integrins from
the rear of the cell to newly forming focal adhesions at the leading edge; now, however, it is
thought that the recycling is more localized, at least in non-dividing cells. It has also become
clear that there are reciprocal effects on recycling between integrins and other receptors,
with, for example, integrin engagement affecting RTK trafficking and vice versa (Caswell et
al., 2008; Wickstrom and Fassler, 2011). Internalization of certain integrins via clathrin-
coated vesicles is clearly an important aspect of focal adhesion disassembly and integrin
trafficking. The cytoplasmic tails of integrin beta subunits contain NXXY motifs that
associate with clathrin adaptors such as AP2, while adaptors such as Dab and Numb, which
contain phosphotyrosine binding domains, can interact with NPXY motifs in certain beta
tails (Margadant et al., 2011). However, certain integrins are also known to be internalized
by clathrin-independent mechanisms. For example, αvβ3 and α5β1 have been reported to
internalize via lipid raft or caveolar mechanisms, as has α2β1 (Karjalainen et al., 2008),
while macropinocytosis has also been observed in internalization of integrins during cell
migration (Gu et al., 2011). (see Figure 5).
While in some cases integrins can be ubiquitinated and thus targeted for lysosomal
degradation (Lobert et al., 2010), for the most part un-liganded internalized integrins recycle
back to the cell surface. Thus after entry into Rab5 positive early endosomes integrins can
recycle to the plasma membrane via a Rab4 associated ‘short loop’ or via a ‘long loop’
involving the Rab11 positive perinuclear recycling compartment. For example, several
studies have found that αvβ3 primarily recycles via the Rab 4 pathway while α5β1
primarily uses the Rab11 pathway (Caswell et al., 2009). Recent evidence has indicated that
certain Rab proteins can associate with integrin cytoplasmic tails either directly (Rab 21
with α2 and α5)(Mai et al., 2011) or via multiprotein complexes. The process of integrin
trafficking clearly plays a key role in the regulation of cell motility; thus the appropriate type
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and amount of integrin needs to be delivered to the advancing front of the cell and, as
discussed above, integrins are key regulators of Rho-family GTPases and thus essential to
control of the cytoskeleton.
Differential Expression of Integrins—Since they are structural as well as signaling
proteins integrins are usually expressed at relatively high levels. For example, the αIIbβ3
integrin is present at several tens of thousand of copies per platelet (Savage et al., 1990),
while αvβ3 is found in several tumor cell lines at levels of ~1–3 x105 copies per cell
(Mulgrew et al., 2006), or, in other terms, the αvβ3 integrin is present in a tumor cell line at
15000 fmol/mg membrane protein (Szabo et al., 2012). These are relatively high numbers
for receptor expression. More important than absolute numbers is the differential expression
of various integrins in individual tissues or under differing physiological conditions. While
most tissues/cell types express several different integrins, there are some notable examples
of specificity. Thus αIIbβ3 is exclusively expressed in platelets (or their precursors) while
the β2 family of integrins is expressed only in leukocytes. There are a number of examples
of altered expression of integrins in cancer, although the literature on this topic is complex
and often confusing (Desgrosellier and Cheresh, 2010; Guo and Giancotti, 2004; Moschos et
al., 2007). One clear finding is the increased expression of the αvβ3 integrin during tumor
angiogenesis (Avraamides et al., 2008); this has led to enormous interest in using selective
ligands for αvβ3 to image or treat the tumor vasculature (Niu and Chen, 2011). Increased
expression of particular integrins has been associated with progression or poor prognosis in
certain cancers; for example, αvβ6 in several carcinomas, α6β4 in breast cancer, and αvβ3
in melanoma and glioblastoma (Desgrosellier and Cheresh, 2010). On the other hand α2β1
may function as a tumor suppressor, while α5β1 can paradoxically inhibit transformation
although it is sometimes over-expressed in tumors. Unfortunately, there is not a systemic
body of information concerning integrin expression at the protein level in tissues or in
tumors. However, if one makes some assumptions about the correlation between mRNA and
protein levels, there is abundant information available in the various gene expression
databases such as those from EMBL-EBI or NCBI. For example, this entry provides data on
expression profiling of the human beta 2 integrin in a variety of tissues and disease states.
(http://www.ebi.ac.uk/gxa/gene/ENSG00000160255#list.pagenum=1). Similar data are
available for virtually all integrin subunits and may at least provide initial guidance as to
differential expression in various cell types.
Integrin Ligands—One of the virtues of integrins as potential mediators of selective
oligonucleotide delivery is the existence of a variety of highly selective integrin ligands, as
well as detailed information about how the ligands affect integrin structure and function
(Shimaoka and Springer, 2003). As mentioned above the endogenous ligands for integrins
are all large proteins, either from the ECM, or in the case of β2 integrins intracellular
adhesion molecules of the ICAM family (Humphries et al., 2006). However, the last decade
has seen the development of a wealth of small molecule ligands particularly for αIIbβ3,
αvβ3 and α4β1. Integrin ligands bind in the cleft between the α and β subunits and virtually
all small molecules are ligand mimetic competitive inhibitors. Interestingly however, some
antagonists can partially induce the activated (extended) conformation of the integrin
(Shimaoka and Springer, 2003); thus responses can be complex. A vast amount of
information on small molecule ligands of integrins is available in the Binding DB; for
example, this entry lists ligands for the integrin α4β1 (http://www.bindingdb.org/bind/
ByPubMed_server.jsp?target=Fibronectin%20receptor%20beta/Integrin%20alpha-4) while
entries for many other integrins are also found at this web site.
The most highly developed group of integrin ligands are the small molecule inhibitors of the
platelet αIIbβ3. Epifibatide and Tirofiban have been in the clinic for almost two decades and
have been beneficial in several acute coronary syndromes; however, their use has declined
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somewhat with the advent of orally available anti-platelet drugs that affect the P2Y12
receptor (Kristensen et al., 2012). A variety of analogs of Tirofiban have been developed but
are not in clinical use (Millard et al., 2011).
The α4β1 integrin plays a key role in leukocyte endothelial cell interaction and has thus
been of interest in terms of modulating inflammatory processes (Jackson, 2002). Several
small molecule antagonists of α4β1 are in clinical trials but there have been issues
concerning their effectiveness and potential toxicities (Millard et al., 2011).
Perhaps the most complex and interesting situation concerning specific integrin ligands
involves inhibitors of αvβ3. The apparent key role of this protein in tumor angiogenesis as
well as its over-expression in several refractory cancers such as glioblastoma provoked rapid
development of both monoclonal and small molecule inhibitors. The most advanced of the
latter is Cilengitide a cyclic pentapeptide containing the RGD sequence that is a highly
selective inhibitor of the avb3 and avb5 integrins (Desgrosellier and Cheresh, 2010; Millard
et al., 2011). The rationale for the development of this drug is that multiple observations in
cell culture and in animal tumor models have shown that blocking αvβ3 in various ways
reduces angiogenesis. However, there has always been controversy in this area since genetic
ablation of av in mice does not completely block angiogenesis (Hynes, 2002b). Cilengitide
has been in advanced clinical trials but results have been somewhat disappointing (Millard et
al., 2011). Recently an interesting possible explanation has emerged from studies of integrin
effects on trafficking. The vascular endothelial growth factor (VEGF) receptor VEGFR2
(FLK1) is central to the angiogenic process (Zhu and Witte, 1999). Interestingly when αvβ3
is functional, VEGF induced recycling of FLK1 is limited and the receptor is degraded in
lysosomes. However, when αvβ3 is inhibited, a Rab4 mediated rapid recycling pathway
carries FLK1 back to the plasma membrane where it can be re-stimulated by VEGF leading
to increased angiogenesis (Caswell et al., 2009). Thus, cilengitide, as well as other αvβ3
inhibitors, may be caught in a push-pull situation where they both block and promote tumor
angiogenesis. On a brighter note, cyclic peptide antagonists of avb3 have shown great
promise for the targeting of imaging agents to tumors (Chen, 2006). Similar molecules have
also been explored for oligonucleotide delivery in the form of peptide-oligonucleotide
conjugates (Alam et al., 2008; Alam et al., 2011) or as part of various lipid or polymer based
nanoparticles (Juliano et al., 2011), but potential toxicities have not been fully explored.
Integrins offer substantial promise as mediators of selective oligonucleotide delivery.
Members of this receptor family are usually expressed at high levels, they traffic actively
between the cell surface and endosomal compartments and their trafficking pathways are
relatively well understood, in some cases they are differentially expressed in particular
tissues or pathological conditions, and a wealth of high affinity peptide and peptidomimetic
ligands exist. Despite these advantages there are some concerns about utilizing integrins for
targeting. The primary issue is that integrins play key roles both in cell structure and in
signal transduction. Thus the use of integrin ligands to deliver oligonucleotides runs the risk
of compromising essential cellular functions; this may be particularly relevant when
multiple copies of the integrin ligand are used, as in the case with most nanocarrier systems.
The example of Cilengitide, discussed above, provides a warning that use of ligands that
perturb integrins can have unexpected negative consequences.
Receptor Tyrosine Kinases
Agents that inhibit receptor tyrosine kinases (RTKs), both monoclonals and small
molecules, have become important tools in cancer therapy (Ciardiello and Tortora, 2008;
Gschwind et al., 2004). This is because RTKs, also known as growth factor receptors, play
an absolutely key role in signal transduction processes that regulate cell proliferation.
Additionally, many malignancies are driven by mutations in RTKs or by their altered
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expression. In humans the RTK family is comprised of 58 members grouped into multiple
subfamilies. Each RTK has a large extracellular domain, a single transmembrane segment
and a cytosolic region that includes a tyrosine kinase domain. The extracellular domains of
RTKs are quite varied, perhaps reflecting the diversity of their ligands; however, there is
substantial conservation of the basic organization of the kinase domains. All RTKs are
activated by essentially the same basic mechanism (Hynes and Lane, 2005; Lemmon and
Schlessinger, 2010); binding of the specific growth factor causes dimerization (or
oligomerization) leading to activation of tyrosine kinase activity and cell signaling. Many
growth factors are themselves dimeric and in some cases, such as Trk A, the nerve growth
factor receptor, the dimeric ligand simply bridges between two receptors. However, in other
cases binding of the ligand induces conformational change in the receptor and dimerization
takes place purely via receptor domain interactions, for example, in the epidermal growth
factor receptor family (EGFRs).
RTK Signaling—Ligand binding and dimerization of RTKs leads to autophosphorylation
of their cytosolic regions, as well as tyrosine phosphorylation of bound partner proteins
(Koch and Claesson-Welsh, 2012; Lemmon and Schlessinger, 2010). There are complex
relationships between autophosphorylation patterns and progressive activation of kinase
catalytic activity, with the details varying between different RTKs. The net result is the
creation of multiple phosphorylated tyrosines that can then serve as docking sites for
proteins containing SH2 or PTB domains. In many cases the phosphotyrosine binding
proteins are, or are bound to, enzymes involved in further steps of signal transduction. Thus
the initial activation of the RTK leads to the creation of a multi-protein signal transduction
hub (see Figure 4). The classic example of this is the relationship between the EGFR and
signaling through the mitogenic Erk/MAP kinase pathway (Chang and Karin, 2001). Thus
upon autophosphorylation of the EGFR cytoplasmic domain the SH2 domain adapter protein
Grb2 binds to phosphotyrosine residues, particularly Y-1068 in the tail region (Batzer et al.,
1994). Grb2 is constitutively associated with SOS, a GEF for the Ras small GTPase. This
activates Ras to its GTP loaded form whereupon it can bind to and activate Raf-1, the
upstream kinase in the MAP kinase cascade, and recruit it to the plasma membrane. This is
followed by Raf activation of MEK, a dual specificity kinase, MEK activation of the Erk
MAP Kinase, and finally migration of Erk to the nucleus where it phosphorylates and
activates ETS family transcription factors that contribute to cell cycle control and
proliferation. While this classic example of RTK signaling nicely illustrates ideas about
multi-protein complexes and the triggering of pathways, we now know that the reality is far
more complex. Rather than triggering simple linear pathways, RTK activation modulates
complex signaling networks (Lazzara and Lauffenburger, 2009; Rangamani and Iyengar,
2008) that include multiple branch points and negative and positive feedback loops.
RTK Trafficking and Recycling—The intracellular trafficking of RTKs is a key aspect
of their function (Parachoniak and Park, 2012). As in the case of signaling transduction, the
trafficking of RTKs often involves multiple interacting processes rather than simple linear
pathways (Zwang and Yarden, 2009). The EGFR is one of the better-studied RTKs in terms
of trafficking and can serve as an example for other receptors (see Figure 5). Thus the
cytosolic tail of liganded EGFR interacts with adapter proteins such as AP-2 to cluster the
receptor in clathrin-coated pits. After scission of the coated vesicles from the membrane by
dynamin and release of the clathrin coat, the liganded EGFR enters early endosomes and is
then subsequently trafficked to late endosomes/multi-vesicular bodies and then to
lysosomes, where both ligand and receptor are degraded thus terminating signaling
(Lemmon and Schlessinger, 2010). However, in some circumstances EGFR (as well as other
RTKs) can enter cells via a non-clathrin pathway and/or recycle back to the plasma
membrane. Ubiquitination of the EGFR by the c-Cbl E3 ubiquitin ligase is a key aspect of
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targeting the receptor for degradation via recognition by the ESCRT complexes in
multivesicular bodies followed by sorting to lysosomes (Sorkin and Goh, 2008). It should be
noted, however, that EGFR remains liganded and activated throughout much of the
trafficking process and is thus capable of signaling. Interestingly, internalization of EGFR is
essential for signaling to one of its downstream pathways (that involving the AKT kinase)
but not for signaling in the Erk/MAP kinase pathway (Goh et al., 2010). Other instances of
interplay between the signaling and trafficking pathways of RTKs abound in the literature
(Miaczynska and Bar-Sagi, 2010; Sorkin and von Zastrow, 2009). For example, c-Met, the
receptor for hepatic growth factor, must traffic to a perinuclear compartment in order to
activate STAT3, but this localization is not needed for activation of the MAP kinase
pathway (Kermorgant and Parker, 2008). As compared to the integrin family of receptors,
RTKs tend to recycle to a lesser degree and be more likely to traffic all the way to the
lysosome; however there are many variations on this theme for different members of the
RTK family.
Differential Expression of RTKs—The most prominent example of RTK expression
playing a role in disease is of course the over-expression of HER2 in certain forms of breast
cancer (Shepard et al., 2008). However, differential expression of several RTKs is seen in
different tissues or in various disease states. For example, members of the Trk family of
RTKs are primarily expressed in neuronal or neuroepithelial tissues and may have a role in
neuroblastoma (Brodeur et al., 2009). VEGFR2 is primarily expressed in vascular
endothelial cells, although other members of this RTK subfamily may be expressed
elsewhere (Koch and Claesson-Welsh, 2012). Over-expression of the Mer and Axl RTKs in
certain cancers has recently become of therapeutic interest (Verma et al., 2011). The number
of RTKs per cell can vary widely. For example, in one study the EGFR was present in
various cell lines in amounts ranging from 103 to 106 copies per cell (Imai et al., 1982). In
another study the VEGFR2 was present at about 0.5–1.0 × 105 copies per vascular
endothelial cell (Napione et al., 2012). Thus RTKs are often expressed at levels of thousands
to hundreds of thousand of copies per cell, a potentially useful range in terms of using these
receptors for targeted delivery. Unfortunately there is no systematic information concerning
RTK expression at the protein level; thus the NCBI and EMBL-EBI gene expression
resources are valuable for obtaining initial insights into possible levels of expression.
RTK Ligands—The endogenous ligands for RTKs are all relatively large polypeptides and
thus are not ideal for use in delivery approaches. However, there are a variety of high
affinity monoclonal reagents for the external domains of RTKs (Hynes and Lane, 2005;
Krause and Van Etten, 2005). These can be used themselves as targeting reagents, or
converted to Fab fragments, or reconfigured as scFv reagents (Tohidkia et al., 2012) from
phage display; there are a number of examples of delivery of drugs or nucleic acids with
RTK targeted nanoparticles using antibody based approaches (Hwang et al., 2012; Kirpotin
et al., 2006; Liu et al., 2011). However, in contrast to the situation with integrins or with
GPCRs, there are few small peptide or small molecule ligands for the external binding sites
of RTKs. Thus, for the most part, ligands suitable for direct conjugation with
oligonucleotides are not available for this family of receptors.
Like integrins, RTKs are often expressed at reasonably high levels and thus may offer useful
vehicles for targeted delivery of oligonucleotides. Liganded or antibody clustered RTKs are
primarily internalized via the ‘classic’ clathrin pit pathway and are trafficked through low
pH endosomal compartments and thence to lysosomes. Thus RTKs provide an effective
means of delivery to these compartments; this may offer important opportunities for
pharmacological enhancement, for example by using pH sensitive delivery agents. However,
unlike some integrins that rapidly recycle, the cell surface display of RTKs needs to be
restored by synthesis of new molecules. Thus delivery strategies that involve multiple
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dosing may not be appropriate if RTKs are used for targeted delivery. Perhaps even more
than the case of integrins, RTKs are involved in critical signaling pathways. Thus delivery
approaches that either over-stimulate or inhibit those pathways could be very detrimental to
the cell.
GPCRs
The G protein-coupled receptors (GPCRs) comprise the largest receptor family in the human
genome (Armbruster and Roth, 2005) with about 800 members of which about half are
odorant or taste receptors while the rest control a multiplicity of physiological functions in
the CNS, the cardiovascular system, the GI tract and elsewhere. While GPCRs vary greatly
in primary sequence they share a common topology based on seven transmembrane helices
and are thus sometimes called heptahelical receptors. Broadly speaking, there are three types
of ligands for GPCRs. First, small molecule ligands that bind near the extracellular face in
clefts between the helices; an example would be the beta-adrenergic receptors that are
targets for antihypertensives. Second, polypeptide ligands that bind to the GPCR
extracellular loops; pituitary hormones such as ACTH would be examples of this type.
Finally, in the protease activated receptor (PAR) subfamily (Soh et al., 2010) an external
protease such as thrombin cleaves the extracellular N-terminus of the GPCR to release a
latent peptide agonist.
GPCR Signaling and Trafficking—In their inactive state GPCRs firmly associate with
heterotrimeric G proteins while upon ligand binding a conformational change occurs in the
receptor that results in the exchange of GTP for GDP on the G protein α subunit and release
of both the Gα subunit and the βγ complex (Cabrera-Vera et al., 2003). The G protein
subunits can then interact with a variety of downstream effectors (Gilman, 1995). For
various members of the heterotrimeric G protein family the effectors would include
adenylate cyclase, phospholipase Cβ and various ion channels. The GTP loading and
activity of the Gα subunit is negatively regulated by members of the RGS protein family
(Kimple et al., 2011). (see Figure 4).
The signaling activity of GPCRs is highly interconnected with their endocytosis and
intracellular trafficking (Drake et al., 2006; Hanyaloglu and von Zastrow, 2008). (see Figure
5). Internalization of GPCRs can desensitize the receptor thus reducing signaling via
‘classical’ second messengers such as cyclic AMP, but can also result in the creation of new
signaling processes with different downstream effectors. Internalization of agonist activated
GPCRs begins with the phosphorylation of their cytoplasmic tails by a family of GPCR
Kinases (GRKs). This results in the recruitment of an adaptor protein termed β-arrestin that
in turn can interact with the AP-2 adaptor thus recruiting clathrin and segregating the GPCR
into coated pits. Thus for many GPCRs the primary route of internalization of agonist-
activated receptors is via the clathrin-dependent endocytotic pathway. However, it should be
noted that GPCRs have also been observed in association with lipid rafts/caveolae.
Importantly, GRK action and β-arrestin binding inactivate the GPCR before internalization
is fully manifested; thus desensitization involves more than simple removal of the receptor
from the cell surface. Subsequent to trafficking to Rab5 positive early endosomes, the
internalized GPCR can undergo two distinct fates. One possibility is return to the plasma
membrane via Rab4- or Rab11-positive recycling endosomes. However, GPCRs can also be
sorted to multivesicular bodies and thence to lysosomes where they are degraded; this
process depends on receptor ubiquitination by E3 ligases. The degradation of GPCRs is a
slow process compared to the initial desensitization, but it has the effect of a gradual
reduction of available receptors in the cell.
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The formation of the GPCR/β-arrestin complex on the cytosolic face of endosomes has
important signaling consequences. In essence, the GPCR and β-arrestin form a G protein-
independent signaling complex, with β-arrestin serving a key role as a scaffold protein. Thus
β-arrestin can associate with several key mitogenic signaling molecules such as the c-Src
tyrosine kinase and members of the MAP kinase cascade, including Erk itself, thereby
projecting GPCR signaling into these pathways (Shukla et al., 2011). In effect, the
endosome-localized GPCR/β-arrestin complex forms a ‘signalosome’ that is biochemically
distinct and topographically separated from GPCR/G-protein complexes at the cell surface.
However, there is data suggesting that some of the ‘classic’ signaling effectors such as
adenylate cyclase may also function from an endosomal location, but with different kinetics
(Calebiro et al., 2010). Thus the story of role of β-arrestin and GPCR internalization in
signaling has grown increasingly complex and is only touched on here.
An additional important aspect of GPCR signaling concerns ‘cross-talk’ or ‘transactivation’
between GPCRs and RTKs. Agonist stimulation of certain GPCRs can lead to parallel
activation of RTK signaling pathways; this can involve several distinct mechanisms
(Natarajan and Berk, 2006). First, GPCR signaling can cause the activation of proteases that
cleave the precursor forms of growth factors leading to release of active factor and RTK
stimulation. Second, GPCR activation can lead to generation of reactive oxygen species that
can affect RTK signaling. Third, GPCRs and their adaptor proteins can associate with RTKs
and their adaptors to create specialized signaling domains in the membrane leading to
enhanced activity (Pyne and Pyne, 2011). Finally, as discussed above the GPCR/arrestin
complex can directly signal to elements downstream or RTK activation such as the MAP
kinase cascade. Receptor transactivation is a rapidly expanding area of research and
additional mechanisms may come to light.
Differential Expression of GPCRs—Many GPCRs have distinct distributions in tissues
or have altered expression levels in disease states. Perhaps the most elegant example is
rhodopsin, the photon sensitive GPCR that is uniquely expressed in the retina. A number of
GPCRs including several orphan receptors with unknown ligands have been reported to be
overexpressed in various cancers (Li et al., 2005). For example, overexpression of the
gastrin releasing peptide receptor GRPR has been implicated in a number of cancers
(Cornelio et al., 2007) and radiolabeled GRPR ligands have been used for tumor imaging
(Garrison et al., 2007). We have also used a peptide ligand for GRPR to deliver
oligonucleotides to GRPR-positive tumor cells (Ming et al., 2010). In another disease
context, variations in the expression of β and α adrenergic receptors and of angiotensin
receptors have been observed in various stages of heart disease (Salazar et al., 2007).
Because of their longstanding pharmacological importance and the existence of convenient
radioligand binding assays, there is more information readily available on the abundance of
GPCRs at the protein level than for other receptor families. The expression of GPCRs varies
widely between receptor types and between tissues and cell types, but in general is lower
than expression levels of integrins or RTKs. For example, rat cardiac myocytes were found
to have about 2×105 beta adrenergic receptors per cell (Post et al., 1995) a relatively large
number, while erythrocytes had about 103 copies per cell (Levitzki et al., 1974). P2Y1
receptors were expressed in rat brain at a level of about 50 fmol per mg protein (Houston et
al., 2006) and beta receptor in human iris at about 100 fmol per mg (Wax and Molinoff,
1987); these numbers might be compared to 15000 fmol/mg for the αvβ3 integrin in tumor
cells (Szabo et al., 2012). As a broad generalization, GPCRs tend to be present at 103 to 104
copies per cell as compared to roughly 105 per cell for integrins.
Ligands for GPCRs—Molecules that act on GPCRs account for approximately 40% of
all clinically utilized drugs; further, GPCRs may comprise about 28% of the ‘druggable
genome’ and are subject of continuing active drug discovery research (Filmore, 2004;
Juliano et al. Page 12













Hopkins and Groom, 2002). Thus there exists a huge stockpile of GPCR ligands, including
both those used clinically and molecules that were abandoned during the development
process. While the majority are small organic molecules there are also a large number of
peptide ligands for various GPCRs. There is a vast amount of information on GPCRs and
their ligands in the International Union of Basic and Clinical Pharmacology (IUPHAR) data
base (http://www.iuphar-db.org/index.jsp).
As with integrins and RTKs, delivery strategies utilizing GPCRs must be concerned about
compromising critical downstream signaling pathways. Additionally GPCRs present some
unique opportunities as well as challenges for drug delivery. On the positive side, the
signaling and trafficking pathways for GPCRs are relatively well understood. Further, there
is a plethora of selective high affinity ligands available for possible conjugation directly to
oligonucleotides or to nanocarriers. On the negative side GPCRs are usually not very
abundant and thus their ability to convey large amounts of material to the cell interior may
be limited. A more subtle issue concerns the small molecule nature of most GPCR ligands.
Obviously the original ligand will need to be modified with a reactive group in order to be
chemically coupled to the oligonucleotide or carrier. For small molecules it can be difficult
to add such groups without compromising the affinity or selectivity of the original ligand. In
our experience, in terms of direct conjugation to oligonucleotides, we have had both
successes (Nakagawa et al., 2010) and failures. For a more extended discussion of this issue
see the following reference (Juliano et al., 2012b).
Tissue Specific Receptors- the Heart
In addition to discussion of broad families of receptors, it is worth noting some individual
receptors that have restricted tissue distributions and thus might serve as useful vehicles for
tissue selective oligonucleotide delivery. Thus in the section below we examine a receptor in
the heart and several liver receptors.
A targetable receptor in the heart?—The urotensin receptor (UT), formerly GPR14, is
a G-protein coupled receptor that is expressed in cardiovascular, renal, central nervous
system, and endocrine tissue (Yoshimoto et al., 2004). Within the cardiovascular system the
UT is widely distributed and is present in cardiac myocytes, vascular smooth muscle cells
and endothelial cells (Ames et al., 1999). Activation of the UT induces contraction of
smooth muscle cells and may be a driver of cardiovascular disease. Indeed, there is an up-
regulation of UT expression in many pathologies of the cardiovascular system including
heart failure (Douglas et al., 2002; Zhu et al., 2006), atherosclerosis (Bousette et al., 2004),
and the receptor expression is proportional to the severity of infarct during myocardial
infarction (Tzanidis et al., 2003). The increase in receptor density in the pathologic tissue
makes the urotensin receptor an intriguing target for directed delivery in cardiovascular
disease.
Urotesin II (UII), the first UT ligand discovered, is an endogenously expressed
hendecapeptide (Ross et al., 2010) and it was further determined that the seven C-terminal
amino acids were key to binding to UT. The UII-related peptide (URP), Ala-Cys-Phe-Trp-
Lys-Tyr-Cys-Val, is an octapeptide which contains the seven C-terminal amino acids of UII
and has a high potency (EC50 = 4.8 nM) and high affinity (Kd = 170 pM) for the UT. It has
been suggested that URP acts as an endogenous functional agonist (Sugo and Mori, 2008).
The relatively small size and high receptor specificity makes URP a potential conjugation
factor for targeted drug delivery to tissue expressing the urotensin receptor. However, since
activation of the UT is involved in the progression of cardiovascular disease an agonist
conjugate may prove to be counterproductive to therapy. Other peptides and non-peptide
small molecules have been synthesized as antagonists to the UT receptor (Zhu et al., 2006)
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that may serve as both as inhibitors of UT second messenger signaling as well as mediators
of drug delivery. The urotensin receptor is rapidly internalized upon ligand binding with a
halftime of 5.6 minutes and is rapidly recycled back to the membrane, within 60 minutes of
ligand removal (Giebing et al., 2005). However, dependency of the urotensin receptor on
arrestin for internalization is not clear (Giebing et al., 2005; Proulx et al., 2005). Upon
internalization the urotensin receptor co-localizes with markers of early endosomes (EEA1)
but not with markers of late endosomes or lysosomes (Rab9 and LAMP-1), indicating that
the receptor is recycled back to the cellular membrane early in the trafficking process. These
data suggest that, in addition to up-regulated expression in cardiovascular disease and high
ligand affinity, the UT is readily accessible for ligand binding due to rapid trafficking and
recycling – making the UT potentially an ideal candidate for targeted drug delivery.
Tissue specific receptors- Liver and Kidney
Antisense, and to some extent siRNA, oligonucleotides are distributed to the liver after
intravenous administration without delivery systems (Juliano et al., 2009), which provides
opportunity for using therapeutic oligonucleotides to treat liver diseases. The challenge for
this method is to target specific intrahepatic cell types for effective and safe therapy, as the
cell types play different roles in pathogenesis of liver diseases (Poelstra K, 2012). Utilization
of membrane receptors that are selectively expressed in different cell types in the liver will
provide opportunity for cell specific drug targeting. Thus, we will introduce several major
receptors in the liver that have been used for targeted delivery of drugs, especially
therapeutic oligonucleotides.
The asialoglycoprotein receptor—The asialoglycoprotein receptor (ASGPR) is a C-
type lectin receptor expressed on the sinusoidal membrane of the hepatocytes (Zelensky and
Gready, 2005). Its primary role is to remove N-acetylgalactosamine (GalNAc) and galactose
(Gal)-containing glycoproteins by mediating the capture, endocytosis, and lysosomal
degradation of the substrates (Stockert, 1995). ASGPR targeting can be employed for drug
delivery to hepatocytes by coupling galactose residues or lactose moieties to drug or their
carriers (Poelstra et al., 2012). ASGPR is a high-capacity but low affinity receptor and
multivalent galacotose ligands are often utilized to enhance the binding affinity of
monosaccharides to the receptor (Khorev et al., 2008). Thus, incorporation of multiple
ligands in nanoparticles can achieve higher specificity and efficiency for ASGPR targeting.
For example, multiple GalNAc ligands and PEGs were conjugated to a membrane-active
polymer, which was also linked to a molecule of siRNA (Rozema et al., 2007). When the so-
called “PolyConjugates” are delivered into the hepatocytes by ASGPR-mediated
endocytosis, the polymer is activated in the acidic environment of endosomes, and then
triggers the endosomal release of the conjugates, which is followed by gene silence of the
target genes (Rozema et al., 2007). Therapeutic outcome has been demonstrated when using
this conjugate to deliver apoB siRNA to the liver by intravenous injection (Rozema et al.,
2007). This study highlights the importance of multivalent ligands and endosomal-release
functionality in effective siRNA delivery.
Lipoprotein receptors—Hepatocytes highly express lipoprotein receptors, including
low-density lipoprotein (LDL) and high-density lipoprotein (HDL) receptor, for transport of
cholesterol (Brown and Goldstein, 1985). They have been utilized to deliver
oligonucleotides into hepatocytes by conjugating oligonucleotides with cholesterol and then
complexing the conjugate with the lipoproteins. A recent study indicated that cholesterol-
siRNA conjugates preassembled with HDL or LDL further improved liver uptake and RNAi
activity compared to the “free” cholesterol-siRNA conjugate (Wolfrum et al., 2007).
Knocking out the HDL or LDL receptors reversed the improvement of hepatic uptake of the
conjugate-lipoprotein complexes, suggesting that cholesterol-siRNA generates in vivo RNAi
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by forming lipoprotein particles that are internalized by receptor-mediated endocytosis
(Wolfrum et al., 2007). Interestingly, this targeted delivery system does not include any
endosomal-release functionality. In the endocytosis of lipoprotein particles, cholesterol is
released from lysosome and is available to the cell for new membrane synthesis (Brown and
Goldstein, 1985). It is still unknown whether siRNA-cholesterol conjugates can be released
from lysosome by this mechanism. However, it may indicate that choosing receptor-
mediated endocytosis pathways that end with cargo release in the cytosol may provide
effective delivery systems for transporting oligonucleotides to their pharmacological sites in
the cytosol and nucleus.
Receptors on hepatic stellate cells—Hepatic stellate cells (HSCs) play a key role in
pathogenesis of liver fibrosis (Hernandez-Gea and Friedman, 2011). Thus selectively
targeting anti-fibrotic agents to hepatic stellate cells may provide effective and safe
treatment for liver fibrosis. Mannose-6-phosphate/insulin growth factor type 2 receptor
(M6P/IGF2R) is a primary target for HSC targeting, since its expression is increased when
HSCs are activated during fibrosis (Saperstein et al., 1994). M6P/IGF2R targeting can be
achieved by coupling M6P moiety to drug or their carriers (Beljaars et al., 1999). In one
example, M6P-PEG was conjugated to the sense strands of siRNAs via disulfide linkage,
and the result siRNA conjugates silenced reporter gene expression by 40% in a rat HSC cell
line (Zhu and Mahato, 2010). HSCs are depositories of 50–80% of vitamin A (retinol) in the
whole body and thus have an outstanding capability of transporting vitamin A, most likely
through receptor-mediated endocytosis of retinol binding protein (Senoo et al., 2010). Thus,
vitamin A has also been formulated into liposomes for siRNA delivery to HSCs (Sato et al.,
2008). After systemic administration, the siRNAs targeting heat shock protein were
delivered to HSCs via retinol-binding proteins, leading to the cure of liver fibrosis in rats
(Sato et al., 2008). In spite of the outstanding RNAi activity in vivo, the receptor has not
been identified and thus endocytosis mechanisms for this delivery system are unclear.
Kidney specific receptors—Compared to the liver or tumors, less work has been done
on targeting membrane receptors in the kidney for drug and gene delivery (Dolman et al.,
2010; Shimizu et al., 2010). Most of the successful cases utilized lysozyme as a delivery
carrier and targeted megalin, a receptor in the apical membrane of PTECs mediating
endocytosis of small proteins such as lysozyme that are filtered in renal glomeruli (Dolman
et al., 2010). Therapeutic siRNAs have been applied to treat kidney diseases in animals,
however, most of the studies have utilized endogenous uptake of naked olignucleotides in
renal tubular cells (Molitoris et al., 2009; Vaishnaw et al., 2010; van de Water et al., 2006;
Zheng et al., 2008). Two-photon microscopy in live rats demonstrated that fluorescent
labeled siRNAs mainly accumulate in the renal proximal tubules after quick cellular entry
from the apical membrane (Molitoris et al., 2009). This study supported the notion that
siRNAs enter renal proximal tubular cells by receptor-mediated endocytosis. However, the
receptor has not been identified.
Conclusion: Manipulation of Oligonucleotide Targeting and Trafficking for
Enhanced Pharmacological Effects
To summarize, there are two important aspects to the effective targeting of therapeutic
oligonucleotides. The first is to select a receptor/ligand combination that will afford
substantial oligonucleotide accumulation in the cell type of interest while still maintaining a
high degree of selectivity. The second is to overcome the trapping of oligonucleotides in
pharmacologically inert endomembrane compartments.
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In this review we have focused on integrins, ‘classic’ RTKs such as the EGFR, and typical
GPCRs as potential receptors for oligonucleotide delivery. Obviously there are many other
receptor families that could serve in this manner including lectin-like receptors such as the
selectins, cadherin family cell-cell adhesion receptors, the semaphorins, plexins and
neuropilins so prominent in the CNS, the atypical Eph subfamily of tyrosine kinases and
their transmembrane ephrin ligands, the TGF-β/activin family of receptors, the Wnt/Frizzled
signaling pathway, and finally the multiple Ig-domain receptors that are so important in
regulation of the immune system. However, in many of these cases there are few ligands
available that have the appropriate size and chemical characteristics to permit facile
coupling to oligonucleotides or their delivery moieties. Likewise we have not discussed the
folate-folate receptor system; this topic has been frequently reviewed and the advantages
and disadvantages of this approach are well known (Garcia-Bennett et al., 2011; Low and
Kularatne, 2009). With the abundance of information on various receptor families and their
ligands, as well as an ever-increasing repertory of clever coupling approaches such as ‘click
chemistry’ (Juliano et al., 2012b; Yamada et al., 2011), designing targeted oligonucleotide
conjugates or carriers should be the easier of the two problems addressed in this review.
A greater challenge is the release on oligonucleotides from non-productive membrane bound
compartments without causing serious harm to the cell. There has been a huge amount of
work on what are essentially physical approaches to enhancing oligonucleotide delivery.
Thus membrane destabilizing cationic lipids, as well as polymers that produce ‘proton
sponge’ effects, are widely used manifestations of the physical approach to oligonucleotide
delivery. There are numerous excellent reviews on these topics (Nguyen and Szoka, 2012;
Schroeder et al., 2010), including consideration of their toxicities (Akhtar, 2010), and we
will not discuss them further. Rather we will focus on biological and chemical approaches to
manipulating cellular endomembrane compartments. There is a vast amount of information
on this topic that appears in the cell biology literature, but until recently it had not penetrated
the drug delivery literature to any great degree.
A powerful strategy is to use plasmid or viral vectors to express mutant versions of proteins
that play key roles in intracellular trafficking so as to modulate these processes. For
example, constitutively activated Rab proteins have been used to enhance specific aspects of
trafficking pathways, while conversely, dominant negative Rabs cause pathway blockade
(Mainou and Dermody, 2012; Stenmark et al., 1994). This type of approach is just beginning
to be applied in the oligonucleotide field; for example we have used dominant negative
versions of dynamin and caveolin to interdict early steps in uptake of oligonucleotides or of
oligonucleotide/nanocarrier complexes (Alam et al., 2010; Ming et al., 2011)
Although molecular approaches to trafficking pathway manipulation are very powerful
investigative tools, they obviously cannot be used in a therapeutic context. For
pharmacologically significant manipulation of oligonucleotide trafficking one needs to use
small molecules. A number of inhibitors of uptake or trafficking have been known for many
years (von Kleist and Haucke, 2011). Many of these work essentially by physical
mechanisms and are thus rather non-specific. Some examples would include inhibition of
clathrin-mediated endocytosis by K+ depletion or hyperosmolarity, inhibition of calveolar/
lipid raft-mediated processes by extraction/sequestration of cholesterol with cyclodextrins or
filipin, and lysosomotropic drugs like chloroquine that disrupt low pH compartments such as
lysosomes essentially by a protein sponge effect. Most of these physical agents act only at
high concentrations, disrupt many cellular activities, and are quite toxic
More recently a few agents have emerged that manipulate endocytosis and trafficking by
acting on key proteins involved in these processes; thus these agents have true drug-like
properties and could conceivably be used in therapeutic contexts. Perhaps the most widely
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known are dynasore and the dynoles, which inhibit the GTPase activity of dynamin and thus
its function in vesicle budding. The ‘pitstops’ are compounds that bind to the globular
terminal domain of clathrin and immobilize coated pits. Since both pitstops and dynasore/
dynole inhibit endocytosis, they obviously cannot be used to enhance oligonucleotide action,
but they can be useful in exploring uptake mechanisms. Proceeding further into the cell,
there are several sets of compounds that affect the function/stability of endosomes or the
Golgi apparatus. The best known is brefeldin A that inhibits GBF1, BIG1 and BIG2 that are
GEFs for the Arf1 GTPase that is essential for Golgi trafficking. Golgicide is a more
specific compound that selectively blocks GBF1 but not the other Arf1 GEFs. Both
brefeldin A and golgicide cause dispersion of the Golgi network. A compound termed A5 is
thought to block trans-Golgi to endosome traffic by affecting the AP1 adaptor protein. High
throughput screening for agents that inhibit the actions of bacterial and plant toxins led to
the Retro group of compounds. These act by blocking the so-called retrograde trafficking
pathway from endosomes to the trans-Golgi used by some toxins and viruses. Thus there are
now a variety of modulators of endocytosis and trafficking that can be explored in the
context of oligonucleotide delivery (Duncan et al., 2007; Saenz et al., 2009; Stechmann et
al., 2010; von Kleist and Haucke, 2011).
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Figure 1. Routes of Endocytosis
This depicts several of the common pathways of endocytosis including the clathrin-coated
pit/vesicle pathway, the caveolar pathway, macropinocytosis, and clathrin/caveolin-
independent pathways. Key proteins including clathrin, caveolin, dynamin and various Rab
GTPases are shown.
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Figure 2. Intracellular Trafficking
This illustration shows the movement of internalized material (purple circles) from one
endomembrane compartment (DONOR)(1) to another (RECIPIENT) via shuttle vesicles.
This involves pinching off of the shuttle vesicle with the help of a coat protein (2);
uncoating of the vesicle (3); movement through the cytosol on cytoskeletal tracks (4);
recognition of the RECIPIENT using Snares and Tethers (5); and lastly fusion of the shuttle
vesicle with the RECIPIENT membrane using Snares (6).
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Figure 3. The Integrins
This is a depiction of the subunit organization of the integrin family of cell adhesion
receptors. The binding propensities of the various integrins are color-coded. Diagram
adapted from (Margadant, C., H.N. Monsuur, J.C. Norman, and A. Sonnenberg. 2011.
Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol. 23:607-614).
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Figure 4. Signaling by Integrins, RTKs and GPCRs
This illustrates highly simplified versions of the downstream signaling pathways regulated
by these three families of receptors as well as some of the interconnections between
pathways. Cytoskeletal proteins-Talin, Vinculin (Vinc), Paxilin (Pax); Adaptor proteins-
Grb2, Cas, Crk, Pkl, Pix, beta-arrestin (βA); Small GTPases-Ras, Rac, Rho; Heterotrimeric
GTPase (Gα/βγ) Tyrosine kinases-Focal Adhesion Kinase (FAK), c-Src, RTK; Serine-
threonine kinases-PAK, Raf-1, MEK (dual specificity), Erk, Grk; Guanine nucleotide
exchange factors-SOS,DOCK180/ELMO; Metalloprotease (MP).
Juliano et al. Page 28














Endocytosis and Trafficking of Receptors. The left panel illustrates the α5β1 integrin being
internalized via a caveolar pathway to Rab 5 positive early endosomes and then returning to
the cell surface via Rab 11 positive recycling vesicles. The middle panel illustrates EGFR
being internalized in clathrin coated vesicles, entering Rab 5 positive early endsomes and
then, because of previous ubiquitination, being destined for Rab 7 positive late endosomes
and then lysosomes where the receptor is degraded. The right panel illustrates a GPCR being
internalized in clathrin coated vesicles and then returning from early endosomes to the cell
surface via Rab 4 positive recycling vesicles. A portion of the GPCR may also traffic to
lysosomes. The fate of the ligand is not illustrated in these diagrams.
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